Refine
Has Fulltext
- yes (23) (remove)
Is part of the Bibliography
- yes (23)
Year of publication
Document Type
- Journal article (23)
Language
- English (23)
Keywords
- NAFLD (6)
- NASH (5)
- obesity (4)
- fatty liver disease (3)
- apoptosis (2)
- cirrhosis (2)
- fibrosis (2)
- inflammation (2)
- intestine (2)
- 25-hydroxycholesterol 7 alpha-hydroxylase (1)
- ALiOS (1)
- Breath tests (1)
- Drug metabolism (1)
- EQ5D-5L (1)
- Epstein-Barr virus-induced gene 2 (1)
- FIB-4 (1)
- GLP-1 (1)
- Glucose metabolism (1)
- HCC (1)
- HCV infection (1)
- Hepatitis C (1)
- Hepatitis C infection (1)
- IL28B (1)
- Lipid metabolism (1)
- Liver cirrhosis (1)
- M30 (1)
- MASLD (1)
- NLRP3 (1)
- RYGB (1)
- SVR (1)
- T cells (1)
- Transport (1)
- Western diet (1)
- acute hypobaric hypoxia (1)
- adaptive choice-based conjoint (1)
- anemia (1)
- antiviral treatment (1)
- autoantibodies (1)
- beta-oxidation (1)
- bile (1)
- biliary-tract cancer (1)
- biomarker (1)
- burden of disease (1)
- cardiovascular disease (1)
- caspase activation (1)
- ceftriaxone (1)
- chemokines (1)
- cholesterol 25 hydroxylase (1)
- chylomicron (1)
- circulating micrornas (1)
- cytotoxic T cells (1)
- diabetes mellitus (1)
- drug-induced immune hemolytic anemia (1)
- epithelial-mesenchymal transition (1)
- expression (1)
- fat absorption (1)
- fatty liver (1)
- fibrosis progression (1)
- fine-needle-aspiration (1)
- gastric bypass (1)
- gastric emptying (1)
- growth-factor-receptor (1)
- gut–liver axis (1)
- health care resource utilization (1)
- hemolysis (1)
- hepatic stellate cells (1)
- hepatitis C virus (1)
- hepatocellular carcinoma (1)
- host genetics (1)
- human cholangiocellular carcinoma (1)
- human intrahepatic cholangiocarcinoma (1)
- immune cells (1)
- independent marker (1)
- induce cyclooxygenase-2 expression (1)
- inflammasome (1)
- injury (1)
- insulin (1)
- insulin signaling (1)
- interleukin 1 (1)
- interleukin 18 (1)
- keratin-18 (1)
- liraglutide (1)
- liver (1)
- liver disease (1)
- liver diseases (1)
- mammalian genomics (1)
- metabolic syndrome (1)
- miR-122 (1)
- micronuclei (1)
- mouse feeding model (1)
- mouse models DNA damage (1)
- non-alcoholic fatty liver disease (NAFLD) (1)
- non-alcoholic steatohepatitis (NASH) (1)
- nonalcoholic fatty liver disease (1)
- nucleoside transporter (1)
- oxidative stress (1)
- patient preference (1)
- patient-based evidence (1)
- patient-reported outcomes (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- primary biliary cholangitis (1)
- primary sclerosing cholangitis (1)
- protein kinase D2/PKD2/PRKD2 (1)
- psoriasis (1)
- ribavirin serum levels (1)
- salt consumption (1)
- salt-intake-related behavior (1)
- second line therapy (1)
- stable isotope breath tests (1)
- steatosis (1)
- steatotic liver disease (1)
- systemic therapy (1)
- treatment response (1)
- tyrosine-kinase inhibitor (1)
- ursodeoxycholic acid (1)
- vitamin D (1)
Institute
- Medizinische Klinik und Poliklinik II (22)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Pathologisches Institut (2)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
- Institut für Molekulare Infektionsbiologie (1)
- Institut für Pharmakologie und Toxikologie (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Medizinische Klinik und Poliklinik I (1)
- Rudolf-Virchow-Zentrum (1)
EU-Project number / Contract (GA) number
- 678119 (1)
Non-alcoholic fatty liver disease (NAFLD) is rising in prevalence, and a better pathophysiologic understanding of the transition to its inflammatory phenotype (NASH) is key to the development of effective therapies. To evaluate the contribution of the NLRP3 inflammasome and its downstream effectors IL-1 and IL-18 in this process, we applied the true-to-life “American lifestyle-induced obesity syndrome” (ALiOS) diet mouse model. Development of obesity, fatty liver and liver damage was investigated in mice fed for 24 weeks according to the ALiOS protocol. Lipidomic changes in mouse livers were compared to human NAFLD samples. Receptor knockout mice for IL-1 and IL-18 were used to dissect the impact of downstream signals of inflammasome activity on the development of NAFLD. The ALiOS diet induced obesity and liver steatosis. The lipidomic changes closely mimicked changes in human NAFLD. A pro-inflammatory gene expression pattern in liver tissue and increased serum liver transaminases indicated early liver damage in the absence of histological evidence of NASH. Mechanistically, Il-18r\(^{−/−}\)- but not Il-1r\(^{−/−}\) mice were protected from early liver damage, possibly due to silencing of the pro-inflammatory gene expression pattern. Our study identified NLRP3 activation and IL-18R-dependent signaling as potential modulators of early liver damage in NAFLD, preceding development of histologic NASH.
Background: Treatment options for NAFLD are still limited. Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB), has been shown to improve metabolic and histologic markers of NAFLD. Glucagon-like-peptide-1 (GLP-1) analogues lead to improvements in phase 2 clinical trials. We directly compared the effects of RYGB with a treatment using liraglutide and/or peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) in a rat model for early NAFLD. Methods: Obese male Wistar rats (high-fat diet (HFD)-induced) were randomized into the following treatment groups: RYGB, sham-operation (sham), liraglutide (0.4 mg/kg/day), PYY\(_{3-36}\) (0.1 mg/kg/day), liraglutide+PYY\(_{3-36}\), and saline. After an observation period of 4 weeks, liver samples were histologically evaluated, ELISAs and RNA sequencing + RT-qPCRs were performed. Results: RYGB and liraglutide+PYY\(_{3-36}\) induced a similar body weight loss and, compared to sham/saline, marked histological improvements with significantly less steatosis. However, only RYGB induced significant metabolic improvements (e.g., adiponectin/leptin ratio 18.8 ± 11.8 vs. 2.4 ± 1.2 in liraglutide+PYY\(_{3-36}\)- or 1.4 ± 0.9 in sham-treated rats). Furthermore, RNA sequencing revealed a high number of differentially regulated genes in RYGB treated animals only. Conclusions: The combination therapy of liraglutide+PYY\(_{3-36}\) partly mimics the positive effects of RYGB on weight reduction and on hepatic steatosis, while its effects on metabolic function lack behind RYGB.
Background & Aims
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data.
Methods
A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections.
Results
If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0–30%), between 2016–2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15–56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population.
Conclusions
NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden.
Lay summary
Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.